Kuros Biosciences entered into an agreement with Surgical Specialties for distribution of MagnetOs bone graft in the Australian and New Zealand healthcare markets. Sales in Australia are expected to commence in 2020.
Kuros will supply the synthetic graft products, and Surgical Specialties will manage application and maintenance of regulatory and reimbursement approvals in the regions.
MagnetOs’ submicron surface structure, applied during manufacturing, is designed to direct early wound healing toward a bone-forming pathway to support predictable healing and reliable fusion. The products have been granted an osteoinductive claim in Europe.
Kuros Biosciences entered into an agreement with Surgical Specialties for distribution of MagnetOs bone graft in the Australian and New Zealand healthcare markets. Sales in Australia are expected to commence in 2020.
Kuros will supply the synthetic graft products, and Surgical Specialties will manage application and maintenance of...
Kuros Biosciences entered into an agreement with Surgical Specialties for distribution of MagnetOs bone graft in the Australian and New Zealand healthcare markets. Sales in Australia are expected to commence in 2020.
Kuros will supply the synthetic graft products, and Surgical Specialties will manage application and maintenance of regulatory and reimbursement approvals in the regions.
MagnetOs’ submicron surface structure, applied during manufacturing, is designed to direct early wound healing toward a bone-forming pathway to support predictable healing and reliable fusion. The products have been granted an osteoinductive claim in Europe.
Copy to clipboard 
